HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved functional ...
50% of patients (3/6) with baseline HBsAg <1000 IU/mL achieved a functional cure (defined as sustained HBsAg loss and HBV DNA ...
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC ...
A next-generation metagenomic sequencing test developed at UCSF demonstrates its ability to rapidly and accurately diagnose a ...
Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind ...
1d
Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have discovered a significant association between specific Epstein-Barr virus (EBV) variants and nasopharyngeal ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST To access the live ...
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B ...
Screening rates for hepatitis D virus are not ideal among individuals with hepatitis B virus, who also have a higher all-cause mortality rate.
A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV), one of the viruses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback